Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circu...
Abiomed (NASDAQ: ABMD) is a leading provider of...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
DarĂŠ Bioscience is a clinical-stage biopharmaceutical company committed to the ad...
DarĂŠ Bioscience is a clinical-stage biopharmac...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Join the National Investor Network and get the latest information with your interests in mind.